Novartis Stock

Novartis Debt

The Debt of Novartis (NOVN.SW) as of Aug 19, 2026 is 14.64 B USD. In the previous year, Debt was 13.06 B USD — a change of 12.12% (higher).

Debt

14.64 BUSD

YoY

12.12%

Last updated:

In 2026, Novartis's total debt was 14.64 B USD, a 12.12% change from the 13.06 B USD total debt recorded in the previous year.

Access this data via the Eulerpool API

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Debt Details

Understanding Novartis's Debt Structure

Novartis's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Novartis's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Novartis’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Novartis’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Novartis stock

Debt of Novartis is 14.64 B USD in 2026.

Debt of Novartis changed from 13.06 B USD to 14.64 B USD, representing a 12.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Novartis since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Novartis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Novartis

All Key Metrics — Novartis